Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Amgen Inc., and GlaxoSmithKline plc. were Dominating the Global Drug-Device Combination Market in 2020

Global Drug-Device Combination Market is expected to grow with a CAGR of 10.2% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-drug-device-combination-market

The global drug-device combination market is a highly consolidated market, including a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.

The major players dealing in the global drug-device combination market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In September 2018, Amgen Inc. received marketing approval from the Japanese Ministry of Health, Labour, and Welfare for Blincyto (blinatumomab). The first line usage of Blincyto (blinatumomab) is to treat relapsed or refractory B-cell acute lymphoblastic leukemia. This approval has accelerated the company position in the Japanese market

Janssen Pharmaceuticals, Inc, (a subsidiary of Johnson & Johnson Services, Inc.), is the dominating player in the global drug-device combination market. The other key players existing in the market are Medtronic, Zimmer Biomet, Amgen Inc., Mediprint, Propeller Health, B.D., YPSOMED, CosMED Pharmaceutical Co.Ltd., Micron Biomedical, Inc., Findair Sp. z o. o., VAXXAS, MetP Pharma AG, SONCEBOZ, Eitan Medical,  Vaxess Technologies Inc., Subcuject Aps, E3D Elcam Drug Delivery Devices, OcuMedic, GlaxoSmithKline Plc., Bayer AG, NanoPass, Sensirion AG Switzerland, Janssen Pharmaceuticals Inc, (a subsidiary of Johnson & Johnson Services, Inc.), Insulet Corporation, TheraJect, Otsuka America Pharmaceutical, Inc., Raphas Co., Ltd., EOFLOW CO., LTD., CGbio among others.

Drug-Device Combination Market Janssen Pharmaceuticals, Inc, (a subsidiary of Johnson & Johnson Services, Inc.)

Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), founded in 1953, and has headquarters in Belgium. The company is focused on various areas of medicines such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, and pulmonary hypertension. The company has several product categories including SmartJect, TREMFYA and they both are market-focused categories.

For instance,

  • In October 2009, Simponi (Golimumab) received European Approval as a once-monthly subcutaneous anti-TNF for treating rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis with novel Smartject autoinjector. This has strengthened the company’s footprint in Europe and boosted market growth.

The company has a wide presence across the Americas, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies, including Janssen-Cilag A/S (Denmark), Janssen Pharmaceutica (Pty.) Ltd. (South Africa), Johnson & Johnson del Perú SA (Peru), Janssen-Cilag Farmacêutica Ltda. (Brazil), and Janssen Pharmaceuticals, Inc. (the U.S.), among others.

Amgen Inc.

Amgen Inc. was founded in the year 1980, headquartered in Thousand Oaks, California, United States. The company is highly focusing on reducing the cost of healthcare and escalating its market presence.  Moreover, the company is concentrating on R&D on novel human therapeutics for the treatment of serious illnesses. The company operates its business via business segment including human therapeutics, which is the market-focused segment. The company has several product categories, Aimovig, Aranesp, AVSOLA, BLINCYTO, Corlanor, Repatha, Sensipar, Prolia, and Neulasta, among others in which Repatha and Neulasta are the market-focused categories.

For instance,

  • In January 2020, Amgen Inc. announced successful strategic collaboration with BeiGene. It is predicted that this collaboration enhanced the company’s footprints in the China oncology market in the coming years

The company has a presence across North America and the rest of the world. The company also has various subsidiaries, including Alantos Pharmaceuticals Holdings (Delaware), Amgen Canada Inc. (Ontario), Amgen Fremont Inc. (Delaware), Amgen GmbH Germany (Germany). Amgen Ilac Ticaret Limited Sirketi (Turkey), and Amgen S.A.S. (France), among others.

GlaxoSmithKline Plc.

GlaxoSmithKline Plc was founded in the year 1999, headquartered in Greater London, UK. The company's main focus is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company operates its business via several business segments, including pharmaceuticals, vaccines, and consumer healthcare, in which pharmaceuticals are the market-focused segment. The company has several product categories, which are Prescription Medicines and Vaccines, Consumer Healthcare Products, and ViiV Healthcare, in which Prescription Medicines and Vaccines is the market-focused category.

For instance,

  • In October 2020, Glaxosmithkline Plc announced that the European Medicines Agency (EMA) had accepted regulatory submissions seeking approval for the use of anti-IL5 biologic Nucala (mepolizumab) in three additional conditions: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA). This has increased the company’s revenue, thereby attracted more customers towards their company

The company has a presence across North America, Europe, Asia-Pacific, South America, Middle East, and Africa. The company also has various subsidiaries, including GlaxoSmithKline Pharmaceuticals Ltd. (India), GlaxoSmithKline Pakistan (Pakistan), Tesaro (U.S.), GlaxoSmithKline LLC (Canada), and Alacer Corp. (U.S.), among others.